Rankings
▼
Calendar
ABCL Q4 2021 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena
ABCL
AbCellera Biologics Inc.
$1B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$139M
-33.0% YoY
Gross Profit
$117M
84.3% margin
Operating Income
$82M
58.5% margin
Net Income
$60M
43.0% margin
EPS (Diluted)
$0.19
QoQ Revenue Growth
+2429.6%
Cash Flow
Operating Cash Flow
-$17M
Free Cash Flow
-$26M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$293M
Stockholders' Equity
$1.0B
Cash & Equivalents
$476M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$139M
$208M
-33.0%
Gross Profit
$117M
$0
—
Operating Income
$82M
$161M
-49.3%
Net Income
$60M
$117M
-48.8%
Revenue Segments
Royalty
$134M
97%
Research Fees
$5M
3%
License
$86,000
0%
← FY 2021
All Quarters
Q1 2022 →